title: FP-CIT- and IBZM-SPECT in Corticobasal Syndrome: Results from a Clinical Follow-Up Study.
abstract: To evaluate the striatal presynaptic dopamine transporter (FP-CIT-SPECT) and postsynaptic D2 receptor (IBZM-SPECT) binding in patients with corticobasal syndrome (CBS).
  
  
  
  FP-CIT and IBZM are commercially available and approved SPECT tracers for in vivo molecular imaging of pre- and postsynaptic nigrostriatal neuronal degeneration, but only few data for CBS are available.
  
  
  
  23 patients meeting clinical criteria for early- to mid-stage CBS (disease duration ≤4 years) were examined with SPECT radiotracers FP-CIT and IBZM. All suspected CBS patients underwent a clinical follow-up examination and were re-evaluated after 19.7 ± 15.2 months (mean ± SD). Postmortem diagnosis was available for 2 patients. In patients who met research criteria for probable CBS at the final follow-up visit (n = 19; disease duration: 1.95 ± 0.91 years), SPECT binding values were compared to those of age- and gender-matched Parkinson's disease (PD) patients (n = 18, disease duration: 1.92 ± 0.91 years; clinical follow-up: 32 ± 29.6 months) and neurologically normal control subjects (n = 19).
  
  
  
  In comparison to the healthy control subjects, both patient groups showed significant and asymmetric reduction of the striatal presynaptic dopamine transporter binding, but PD patients had significantly lower FP-CIT binding ratios than probable-CBS patients. FP-CIT binding values of probable-CBS patients and healthy controls demonstrated marked overlaps, and in 7 patients (39%) scans revealed no dopaminergic deficit. IBZM uptake did not show significant between-group differences.
  
  
  
  Our data indicate that in the early- to mid-stage CBS the degree of nigrostriatal impairment is only mild with a significant proportion of preserved dopamine transporter binding.
authors.affiliation: Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
authors.forename: Sven
authors.initials: S
authors.lastname: Hammesfahr
authors.forename: Christina
authors.initials: C
authors.lastname: Antke
authors.forename: Eduards
authors.initials: E
authors.lastname: Mamlins
authors.forename: Markus
authors.initials: M
authors.lastname: Beu
authors.forename: Lars
authors.initials: L
authors.lastname: Wojtecki
authors.forename: Stefano
authors.initials: S
authors.lastname: Ferrea
authors.forename: Lars
authors.initials: L
authors.lastname: Dinkelbach
authors.forename: Alexia-Sabine
authors.initials: AS
authors.lastname: Moldovan
authors.forename: Alfons
authors.initials: A
authors.lastname: Schnitzler
authors.forename: Hans Wilhelm
authors.initials: HW
authors.lastname: Müller
authors.forename: Martin
authors.initials: M
authors.lastname: Südmeyer
mesh_terms: D000368:Aged; D001549:Benzamides; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D020734:Parkinsonian Disorders / Q000150:complications / Q000000981:diagnostic imaging* / Q000378:metabolism*; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D014326:Tropanes
chemical_list: D001549:Benzamides; D050483:Dopamine Plasma Membrane Transport Proteins; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D014326:Tropanes; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide